Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.70), $0.10 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $115.5 million versus the consensus estimate of $121.92 million.

GUIDANCE:

Acadia Pharma sees FY2022 revenue of $510-560 million, versus the consensus of $540.7 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.